Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.58 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.49 |
| ▸ | PPARA | Q07869 | 2/20 | 0.47 |
| ▸ | CTSS | P25774 | 3/20 | 0.45 |
| ▸ | CTSK | P43235 | 5/20 | 0.45 |
| ▸ | ATM | Q13315 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 2/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30927572 | 0.91 | PPARA (0.58) | SYKPPARACTSSCTSKATM | |
| SCHEMBL26102167 | 0.90 | SYK (0.52) | SYKCTRB1PPARACTSSCTSK | |
| SCHEMBL26102166 | 0.90 | SYK (0.52) | SYKCTRB1PPARACTSSCTSK | |
| SCHEMBL27179575 | 0.89 | SYK (0.46) | SYKPPARACTSSATMMAPT | |
| SCHEMBL1555742 | 0.85 | SYK (0.57) | SYKCTRB1PPARACTSSCTSK | |
| SCHEMBL1555741 | 0.85 | SYK (0.57) | SYKCTRB1PPARACTSSCTSK | |
| SCHEMBL29997843 | 0.85 | ATM (0.60) | SYKPPARACTSSCTSKATM | |
| SCHEMBL31732152 | 0.85 | SYK (0.69) | SYKCTRB1PPARACTSSCTSK | |
| SCHEMBL31048196 | 0.84 | PPARA (0.52) | SYKPPARACTSSCTSKATM | |
| SCHEMBL16217815 | 0.84 | CTRB1 (0.57) | SYKCTRB1CTSKATMLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250101007-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | LYCIA THERAPEUTICS, INC. | 2025-03-27 | — | — | US | disclosed |
| US-12258332-B2 | ASGPR cell surface receptor binding compounds and conjugates | LYCIA THERAPEUTICS, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| EP-4370157-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | Lycia Therapeutics, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| WO-2024098039-A2 | POTENT ASGPR-BINDING HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-05-10 | — | — | WO | disclosed |
| US-11840691-B2 | Compound and application thereof | KYLONOVA (XIAMEN) BIOPHARMA CO., LTD. (CN) | 2023-12-12 | — | — | US | disclosed |
| US-11840691-B2 | Compound and application thereof | KYLONOVA (XIAMEN) BIOPHARMA CO., LTD. (CN) | 2023-12-12 | — | — | US | disclosed |
| US-20230374513-A1 | NOVEL COMPOUND AND APPLICATION THEREOF | KYLONOVA (XIAMEN) BIOPHARMA CO., LTD. (CN) | 2023-11-23 | — | — | US | disclosed |
| US-20230374513-A1 | NOVEL COMPOUND AND APPLICATION THEREOF | KYLONOVA (XIAMEN) BIOPHARMA CO., LTD. (CN) | 2023-11-23 | — | — | US | disclosed |
| US-20230250091-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | LYCIA THERAPEUTICS, INC. | 2023-08-10 | — | — | US | disclosed |
| US-20230250091-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | LYCIA THERAPEUTICS, INC. | 2023-08-10 | — | — | US | disclosed |
| WO-2023066236-A1 | AGT INHIBITOR AND USE THEREOF | 厦门甘宝利生物医药有限公司 | 2023-04-27 | — | — | WO | disclosed |
| WO-2023288033-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | LYCIA THERAPEUTICS, INC. (US) | 2023-01-19 | — | — | WO | disclosed |
| EP-3992291-A1 | NOVEL COMPOUND AND APPLICATION THEREOF | Kylonova (Xiamen) Biopharma Co., Ltd. (CN) | 2022-05-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230374513-A1 | NOVEL COMPOUND AND APPLICATION THEREOF | GALNT6, GALNT3, GALNT14 | SYK 4804/4885CTRB1 2167/4885PPARA 3113/4885 |
| US-12258332-B2 | ASGPR cell surface receptor binding compounds and conjugates | ASGR1, LAMP2, FCGR2A | SYK 593/4885CTRB1 3034/4885PPARA 2663/4885 |
| US-20250101007-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | ASGR1, LAMP2, FCGR2A | SYK 593/4885CTRB1 3034/4885PPARA 2663/4885 |
| US-11840691-B2 | Compound and application thereof | GALNT6, GALNT3, GALNT14 | SYK 4799/4885CTRB1 2040/4885PPARA 2862/4885 |
| US-20230250091-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | ASGR1, LAMP2, FCGR2A | SYK 593/4885CTRB1 3034/4885PPARA 2663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.